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ABSTRACT
The TMEM165 gene encodes for a multiple pass membrane protein localized in
the Golgi that has been linked to congenital disorders of glycosylation. The TMEM165
protein is a putative ion transporter that regulates H+/Ca++/Mn++ homeostasis and pH
in the Golgi. Previously, we identified TMEM165 as a potential biomarker for breast
carcinoma in a glycoproteomic study using late stage invasive ductal carcinoma
tissues with patient- matched adjacent normal tissues. The TMEM165 protein was
not detected in non-malignant matched breast tissues and was detected in invasive
ductal breast carcinoma tissues by mass spectrometry. Our hypothesis is that the
TMEM165 protein confers a growth advantage to breast cancer. In this preliminary
study we have investigated the expression of TMEM165 in earlier stage invasive ductal
carcinoma and ductal carcinoma in situ cases. We created a CRISPR/Cas9 knockout
of TMEM165 in the human invasive breast cancer cell line MDAMB231. Our results
indicate that removal of TMEM165 in these cells results in a significant reduction of
cell migration, tumor growth, and tumor vascularization in vivo. Furthermore, we find
that TMEM165 expression alters the glycosylation of breast cancer cells and these
changes promote the invasion and growth of breast cancer by altering the expression
levels of key glycoproteins involved in regulation of the epithelial to mesenchymal
transition such as E-cadherin. These studies illustrate new potential functions for this
Golgi membrane protein in the control of breast cancer growth and invasion.

INTRODUCTION

screening have led to an increase in the diagnosis of ductal
carcinoma in situ (DCIS), an abnormal proliferation of
epithelial cells in the breast ducts that has not invaded
tissue and is not cancer. While DCIS is considered a
precursor to invasive ductal carcinoma (IDC) in certain
cases; only 20–50% of DCIS cases will progress to IDC
[2–5]. Currently, there are no efficient diagnostic methods
to distinguish DCIS cases that will remain indolent

Breast cancer is the most commonly diagnosed
cancer in women. It is estimated that 1 in 8 women will
be diagnosed with the breast cancer in the United States
leading to over 252,710 new cases of breast cancer
each year. More than 40,500 women will die of breast
cancer each year [1]. Increased rates of mammography
www.oncotarget.com
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from those that will progress to IDC. The discovery of
molecular markers that could identify DCIS cases with
a higher risk of progression to invasive cancer would
be a significant clinical advance. Studies have revealed
that many factors including altered patterns of gene
expression and post-translational regulation contribute to
the progression of DCIS to IDC [6–9]. Studies focusing on
the characterization of molecular changes in early disease
that will contribute to the conversion to invasive disease
may lead to biomarkers useful for identifying which cases
of DCIS may progress. TMEM165, a Golgi membrane
protein, was discovered as a potential biomarker for
invasive ductal breast carcinoma in our previous
glycoproteomic study [10]. The TMEM165 protein
was identified by mass spectrometry in invasive breast
carcinoma tissue with no detection in patient-matched
adjacent normal breast tissues. TMEM165 is a gene found
to be a putative ion transporter mutated in patients with
congenital disorders of glycosylation [11–14]. CDGs
are an increasing group of genetic metabolic disorders
that affect protein glycosylation [15]. CDG patients with
TMEM165 mutations were characterized by multiple
system defects and in particular growth retardation due to
bone and cartilage defects [13, 14]. A TMEM165-deficient
zebrafish model exhibited phenotypic patterns such as
bone dysplasia and abnormal cartilage development
similar to the major clinical findings found in the three
patients with a homozygous splice mutation [16].
Recently, CRISPR-Cas9 mediated genome wide screening
in bacterial toxins revealed that TMEM165 as a critical
Golgi protein required for maintaining proper levels of
glycosylation [17].
The expression of TMEM165 is amplified in several
human cancers (Figure 1A). We have analyzed TCGA
breast cancer cases to examine TMEM165 expression
levels in all molecular types of human breast cancer using
UALCAN [18] (Figure 1B). We find that TMEM165 is
amplified across all types of breast cancer compared to
normal breast tissue with IDC cases having the highest
levels of TMEM165 expression. The role of TMEM165 in
normal breast physiology has been examined in lactating
breast tissue. TMEM165 expression was upregulated
during lactation 25 times and downregulated 95 times
in involution [19]. TMEM165 has been demonstrated to
maintain Ca++ and Mn++ ion homeostasis to support
proper lactose synthetase functions during milk production
in lactating breast tissues [20].
In the present study, we report that TMEM165 is
upregulated in human breast cancer cell lines and patient
tumor tissues and increased expression of TMEM165
correlates with poor prognosis in breast cancer patients.
Using a CRISPR/Cas9 mediated TMEM165 knockout in
the human breast cancer cell line MDAMB231 we find
that TMEM165 deletion impaired invasive and migratory
properties in vitro and tumor growth in vivo. We observed
an inverse correlation between the protein expression
www.oncotarget.com

levels of TMEM165 and E cadherin in several human
breast cancer cell lines. Our TMEM165KO xenograft
tumors show a re-expression of E-cadherin. E-cadherin is
a well-known epithelial marker important for maintaining
cell-cell adherens junctions which are crucial for tissue
integrity and control of epithelial-to-mesenchymal (EMT)
transitions during normal development. These findings
place TMEM165 as a potential regulator controlling
the EMT transition [21, 22]. Mechanistically, we found
that TMEM165 expression induced changes in N-linked
glycosylation. Our analysis of xenograft tissues reveals
distinct changes in N-linked glycosylation as a result
of TMEM165KO. Thus, we postulate that TMEM165
plays a key role in modulating breast cancer invasion by
altering N-linked glycosylation leading to the suppression
of E-cadherin levels. Collectively, our data demonstrate
that overexpression of TMEM165 promotes EMT in breast
cancer suggesting a novel role for TMEM165 as a driver
of tumor invasion making it a prognostic marker and
potential therapeutic target for breast cancer.

RESULTS
TMEM165 expression is increased in invasive
breast cancer
We have previously identified TMEM165 as a
potential biomarker in a glycoproteomic analysis of high
grade IDC cases with patient-matched adjacent normal
tissues [10]. The cases that were analyzed in this study
were all stage III or IV IDC. In the current study we
were interested in determining the expression levels of
TMEM165 in early stage (stage 1) IDC and DCIS cases.
We conducted an initial analysis of a small number of
DCIS or DCIS cases with regions of IDC to determine
the TMEM165 levels in early IDC (Table 1, Figure 2A
representative IHC). Over 95 positive cells were scored in
each section and the representative case shown in Figure
2A had an overall intensity score of 8 for IDC with an
overall intensity score of 5 for the DCIS section for the
same patient. All IHC staining results (Table 1) show that
in cases with both DCIS and IDC the TMEM165 levels
increased in IDC in the same tissue section. We have
further investigated the expression of TMEM165 in early
invasive disease using the MCF10DCIS xenograft model.
The MCF10DCIS cell line slowly progresses from DCIS
to invasive lesions in 10 weeks. Data shown in Figure 2B
demonstrate that TMEM165 is not expressed in the
non-invasive stage, increases in the focal invasive stage
while still contained within the basement membrane and
continues to expand expression in the invasive stage. Next
we looked at expression levels for TMEM165 in the TCGA
breast carcinoma database [23]. The expression profile of
TMEM165 among the histological subtypes of invasive
breast cancer indicate that TMEM165 expression occurs
in all subtypes with the highest percentages in the ER
2748
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negative subtypes (Table 2, IDC subtypes). The substantial
number of cases with increased TMEM165 expression led
us to evaluate the prognostic significance of TMEM165
expression in breast cancer using the TCGA data. We find
a highly significant reduction in overall survival in cases
with higher TMEM165 expression (Figure 1C). We have
analyzed TMEM165 expression across a panel of human

breast cancer cell lines. TMEM165 expression levels were
detected by Western blot in ER negative subtypes such
as: MDAMB231 [24], BT549 [25], and HS578T [26]
with no detection in the ER positive subtypesT47D, and
MCF7 [27, 28] (Figure 2C). Real-time PCR analysis was
performed on all cell lines and there was no TMEM165
mRNA detected in MCF7, and T47D cell lines (data not

Figure 1: TMEM165 is increased in many human cancers and correlates with reduced overall survival. (A) Amplification

of TMEM165 in human cancers in the cBioPortal [58, 59]. (B) Analysis of TMEM165 expression levels in molecular subtypes of human
breast cancer using UALCAN. (C) Kaplan–Meier analysis (http://kmplot.com/analysis/index) of OS was plotted for breast cancer patients
(n = 626). The OS was determined to be significantly longer in the TMEM165 low expression group than in the TMEM165 high expression
group. A cutoff value of 1495 was chosen by auto select in the analysis configuration, with the expression value of the probe (218095_s_at)
ranging from 89 to 8312. Upper quartile survival rates (months) for the low and high expression groups were 143 and 68.4, respectively.
www.oncotarget.com
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Table 1: Immunohistochemistry staining for TMEM165 in DCIS and early IDC cases
Cases
20659 DCIS/IDC
13646 DCIS
11697 DCIS/IDC

Stain Result
Pos
Pos
Pos

%cells TMEM165
> 95
> 95
> 95

Location
Perinuclear
Perinuclear
Perinuclear

Intensity Scorea
IDC > DCIS (10 > 8)
8
IDC > DCIS (8 > 5)

Percent positive cells were scored by a Pathologist and the overall intensity score is the mean intensity for all cells analyzed.

a

shown). Overall these results suggest that cell lines that
express the ER receptor have very low or undetectable
levels of TMEM165 protein expression. We observed
an inverse trend between TMEM165 and E- cadherin
expression levels in certain cell lines (Figure 2C).
Cell lines exhibiting less invasiveness (MCF7 and
T47D) expressed higher E-cadherin and non-detectable
TMEM165. Whereas cell lines with high invasiveness
(MDAMB231, BT549, and HS578T) expressed
TMEM165 protein with lower E-cadherin expression
(Figure 2C).
A CRISPR/Cas9 TMEM165 knockout (KO) was
generated using the Claudin-low human breast cancer
cell line MDAMB231 with guide RNAs (gsRNA)
to TMEM165 previously described [29]. We have
validated TMEM165KO cells by Western blot and
immunohistochemistry as shown in Supplementary
Figure 1. TMEM165KO or control cells were stained
with the toxin phalloidin to visualize actin structures
[30]. TMEM165KO cells displayed a significant change
in morphology with reorganization of actin and increased
cell spreading on fibronectin (Figure 2D). TMEM165KO
cells also had elevated levels of E-cadherin compared
with control cells. The levels of vimentin, a marker of
mesenchymal cells, was decreased in TMEM165KO cells
compared to control. Cumulatively these results indicate
a substantial phenotypic change in MDAMB231 cells
following knockout of TMEM165.

(Figure 3C). In addition to the Boyden transmigration
assays we performed invasion assays to determine
invasion though extracellular matrix. TMEM165KO
cells show significant reduction in migration through
extracellular matrix, Figure 3D (***P < 0.0001). We have
performed rescue experiments to confirm that TMEM165
expression is inducing the cell migration. Plasmids
containing TMEM165 as a fusion with GFP [31] were
transiently transfected into MDAMB231 TMEM165KO
and control cell lines. Western blot analysis confirms that
with no transfection or the transfection of vector only
MDAMB231 TMEM165KO cells have no expression of
TMEM165 (Figure 3E). The transfection of TMEM165/
GFP fusion leads to increased expression of TMEM165 in
the control cells with restored expression in TMEM165KO
cells. Wounds healing migration assays were performed to
demonstrate rescue of migration in MDAMB231KO cells
after transfection with the TMEM165/GFP expression
plasmid (Figure 3F and 3G, P < 0.000007). Furthermore,
there is an increased migration in control cells following
transfection with TMEM165/GFP (Figure 3G, P < 0.05).
The rescue of migration in TMEM165/GFP transfected
cells confirms a direct role for TMEM165 in the initiation
of cell migration.

Loss of TMEM165 inhibits breast cancer tumor
growth in vivo
Our in vitro data indicate that knockout of
TMEM165 in MDAMB231 cells by CRISPR/Cas9 gene
editing significantly reduces cell migration and increases
cell spreading. These results led us to investigate the effect
of TMEM165 expression on xenograft tumor growth in
vivo. The tumors of mice injected with TMEM165KO
cells showed a significant reduction in tumor growth
and vascularization as compared to tumors from mice
administered with control cells (Figure 4A representative
tumors, Figure 4B cumulative for n = 10 mice each group).
Immunohistochemistry analysis of xenograft tumors
reveals a loss of blood vessels in the TMEM165KO tumors
on the H & E staining (Figure 4C, top panel). Staining
for the vascular endothelial cell marker CD31 (Figure 4C
lower panel) revealed a reduction in TMEM165KO tumors
confirming reduced tumor vascularization. Tumors from
TMEM165KO cells have lower levels of the proliferation
marker Ki67 compared with control tumors (Figure 4C).
The TMEM165KO tumors have a decrease in vimentin
and an increase in E-cadherin suggesting a reversion to

Loss of TMEM165 inhibits breast cancer cell
migration and invasion
Our discovery of increased expression of TMEM165
in invasive breast cancer led us to investigate the potential
role of TMEM165 in cell migration. We tested whether
TMEM165 expression could alter cell migration and
invasion induced by a wound healing assay or stimulated
in a Boyden chamber transmigration assay. The analysis
of wound healing cell migration assays showed an almost
complete closure of the wound in control cells by 48
hrs post scratch with very limited closure of the wound
in TMEM165KO cells (Figure 3A). Cumulative results
from three separate experiments show highly significant
reduction in cell migration (p < 0.001) Figure 3B. To
further study the invasive potential of TMEM165KO
cells, we performed Boyden chamber transmigration
assays and found that MDAMB231 TMEM165KO
cells have significantly (p < 0.05) reduced migration
www.oncotarget.com
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TMEM165 expression alters N-linked
glycosylation

a more epithelial phenotype compared to control tumors
(Figure 4C). Rescue experiments with transfection of
TMEM165/GFP into MDAMB231 TMEM165KO
cells reduces E-cadherin levels and increases vimentin
confirming that these changes are due to TMEM165
expression (Figure 4D). Cumulatively, these results
indicate that TMEM165 promotes the growth and invasion
of breast cancer.

Mutations in TMEM165 are associated with
congenital disorders of glycosylation. Patients with
these mutations show distinct changes in the N-linked
glycosylation of serum glycoproteins such as transferrin.
Therefore, we want to evaluate whether TMEM165 alters

Figure 2: TMEM165 is increased in human breast cancer tissues and cell lines. (A) Immunohistochemistry staining for

TMEM165 in IDC/DCIS breast cancer, arrows mark regions of IDC and DCIS, Bar = 100 µm. (B) Hematoxylin and eosin staining (top)
and immunohistochemistry staining for TMEM165 (bottom) for MCF10DCIS xenograft tissues non-invasive, focal invasive, and invasive,
Bar = 100 µm. (C) Western blot analysis showing TMEM165 and E cadherin expression levels across different human breast cancer cell
lines. Right panel shows the quantification of TMEM165 and E-cadherin protein levels after normalization with actin (n = 2, *P < 0.05,
**
P < 0.01) (D) Phalloidin staining (top panel) to visualize actin filaments of MDAMB231 Control and MDAMB231 TMEM165KO cells
seeded on fibronectin coated coverslips, Bar = 100 µm. Representative images of MDAMB231 Control and MDAMB231 TMEM165KO
cells seeded on fibronectin coated coverslips stained for Vimentin and E-Cadherin with DAPI stained nuclei. Scale bar, 75 µm.
www.oncotarget.com
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Table 2: TMEM165 expression in IDC vary by molecular subtypes
Subtype

Hormonal Status

Luminal A
Luminal B

ER+ and/or PR+, HER2, low Ki67
ER+ and/or PR+, HER2
(or HER2- with high Ki67)
ER-, PR-, HER2ER-, PR-, HER2+

Triple negative/Basal like
Her 2

Percentage of Breast invasive carcinoma cases
showing alterations in TMEM165 gene expressiona
2%
9%
15%
27%

Database used was The Cancer Genome Atlas (TCGA), Nature (2012).

a

N-linked glycosylation in breast cancer cells. MDAMB231
control and two different clones of TMEM165KO cells
were subjected to PNGaseF treatment, which cleaves all
N-linked glycans including high mannose, hybrid and
complex structures at asparagine residues of N-linked
glycoproteins. Both MDAMB231 TMEM165KO clones
(ACH2 and ACA2) revealed dramatic differences in the
migration of nicastrin (NCSTN) glycoforms. Nicastrin,
an N-linked glycoprotein that is an essential component
of γ-secretase, is required for proper Notch signaling
[32]. The molecular weight of the NCSTN glycosylated
variant in control MDAMB231 cells displays a higher
molecular weight migration for the mature protein; while
TMEM165KO clones display NCSTN glycoforms with a
shift in migration of the mature protein toward a lower
molecular weight (Figure 5A). Changes in the migration
of glycoproteins can be due to changes in levels of charged
glycans versus neutral glycans or may be due solely to
truncation of glycan structures. NCSTN migration was the
same in all cells following PNGaseF treatment indicating
that the changes in migration are due to N-glycosylation
on glycoproteins (Figure 5A). These results indicate that
TMEM165 expression changes N-linked glycosylation in
MDAMB231 cells.
The same CRISPR Cas9 guide RNA targets used in
this study were previously used to create TMEM165KO in
HEK293T and HeLa cell lines [14]. We evaluated NCSTN
glycoforms in control and TMEM165KO for each of these
cell lines and compared this to MDAMB231 cells. Our
data show that TMEM165KO in HEK293T and HeLa cells
display NCSTN glycoforms with migration to a lower
molecular weight than the MDAMB231 breast cancer
TMEM165KO cells (Figure 5B) These results indicate
that the NCSTN glycoprotein from MDAMB231 breast
cancer cells have different glycosylation compared with
HEK293T and HeLa cells. To rescue the altered NCSTN
glycoforms in TMEM165KO cells both TMEM165WT
plasmid and empty vector were transiently transfected in
MDAMB231 cells. These results further confirmed that
altered glycosylation pattern observed in NCSTN was
rescued only in TMEM165KO cells after transfected
with TMEM165WT plasmid and not vector (Figure 5C).
Interestingly, when CDG mutant forms of TMEM165
(R126H and G304R) were transiently expressed in
MDAMB231 cells, N-linked glycosylation was also
www.oncotarget.com

present with NCSTN glycoforms as observed in control
cells (Figure 5D). These results indicate that the changes
that occur in TMEM165 in CDG patients that disrupt
function are not disrupting the function of TMEM165 in
the MDAMB231 breast cancer cells as these mutants were
capable of inducing the glycoform of nicastrin observed in
MDAMB231 control cells.
We sent xenograft tumors from control and
TMEM165KO for analysis using Maldi FTICR IMS
N-glycan imaging to get a preliminary evaluation of
glycosylation variants (Figure 5E). In this method FFPE
tissue sections are treated with PNGaseF to release the
N-linked glycans from glycoproteins. This method allowed
us to spatially localize individual glycan structures to
specific tissue regions [33]. A total of 83 N-glycans were
detected. Many N-linked glycan structures did not show a
change in abundance between control and TMEM165KO
(data not shown). However, certain structures showed
differences in abundance. Overall, our results demonstrate
an increase in bi-antennary sialylated glycans in
TMEM165KO tumors with fucose and an increase in tetraantennary glycoforms with core and/or outer fucosylation
(Figure 5E). We confirmed these findings using analysis
of the MDAMB231 control and TMEM165KO cells
using lectin blot analysis and qRT-PCR analysis. The
lectins AAL, DSL, and SNA recognize core and outer
fucose, β1,4 branched glycans [34, 35], and sialic acid
linked to terminal galactose, respectively [36]. Our lectin
blot analysis confirms an increase in the levels of these
N-linked glycan structures on very specific glycoproteins
in TMEM165KO cells (Figure 5F). There are distinct
glycoproteins with different molecular weights showing
changes in lectin binding. For example, fucose changes
detected by AAL are distributed in low and high molecular
weight glycoproteins. However, changes in sialylation
detected by SNA were limited to high molecular weight
glycoproteins. We performed a lectin blot with ConA to
demonstrate an equivalent loading of glycoproteins in
each lane. Glycan levels are often changing as a result
of changes in the levels of glycosyltransferase (GT)
enzymes. We measured the levels of certain GT enzymes
that produce the N-glycan structures that were increased
in TMEM165KO xenograft tumors using real-time PCR
analysis. Data shown in Figure 5G show the fold change
in relative normalized expression levels for each enzyme
2752
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Figure 3: MDAMB231 TMEM165KO cells have reduced cell migration. (A) Representative phase-contrast images of wound

healing assays captured at 0 and 48 hr time points. Bar = 300 µm (B) Graphical representation of the percent closure from n = 3 wound
healing experiments analyzed using ImageJ. Error bars denote SD; **P < 0.001. (C) Boyden chamber transmigration data from n = 5
experiments showing the number of cells present on the lower compartment of a transwell membrane after 48 h. Error bars denote SD; *P <
0.05. (D) Chemicon (ECM554, Millipore, Billerica, MA) cell invasion assays were performed and cells that invaded ECM were measured
using fluorescent plate reader, error bars denote SD of n = 3 experiments; ***P < 0.001. (E) Western blot analysis showing TMEM165
expression after transient transfection with TMEM165/GFP plasmid and vector in control and TMEM165KO cells. Right panel shows
the quantification of TMEM165 protein levels after normalization with actin (n = 2, *P < 0.05). (F) Representative phase-contrast images
show migration rescue in TMEM165KO after transfection with TMEM165/GFP plasmid compared to the control at the 0 and 24 hr time
points. Bar = 300 µm (G) Graphical representation of wound healing rescue experiments n = 3 analyzed using Image J. Error bars denote
SD; ***P < 0.000007 and *P < 0.05.
www.oncotarget.com
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in control and TMEM165KO cells. The changes in GT
mRNA levels correlate well with the lectin blot data
and the Maldi-FTICR IMS imaging data suggesting that
TMEM165 expression levels change the transcript levels
of these GT enzymes in the N-linked pathway.

studies to identify key regulators will allow for novel
methods to control this pathway for tissue regeneration
and prevention of cancer invasion in the future. Mutations
in the TMEM165 gene have been linked to congenital
diseases of glycosylation where the patients have
significant bone and cartilage growth defects [12, 13].
Therefore, TMEM165 may be a protein required for
mesenchymal transitions. We discovered TMEM165 as a
biomarker for IDC in a glycoproteomics analysis using
high grade IDC tissues with matched adjacent normal [10].
The current study has extended our previous discovery

DISCUSSION
EMT is an essential component of normal
development that is involved in tissue regeneration and
cancer cell invasion [21]. EMT is a dynamic process and

Figure 4: TMEM165 knockout inhibits breast cancer growth in a xenograft model. (A) Representative image of tumors

extracted from nude mice treated with MDAMB231 Control and MDA MB231 TMEM165KO. (B) Cumulative growth curves for
MDAMB231 control cells and MDAMB231 TMEM165KO cell xenografts (n = 10 mice control, n = 10 TMEM165KO; *P < 0.0001).
(C) Representative images of MDAMB231 Control and TMEM165KO derived tumor sections stained for Hematoxylin and eosin (H&E),
Ki67, Vimentin, E-Cadherin, and CD31, bars 100 μm. (D) Western blot analysis of vimentin and E-cadherin expression after transient
transfection with TMEM165/GFP or vector in TMEM165KO and control cells, asterisks mark the vimentin band in Western blots. Lower
panels shows the quantification of Vimentin and E-cadherin protein levels after normalization with ERK (n = 2, **P <0.01). The Western
blot images are cropped and were imaged with Bio-Rad EZ Imager. The second band from the left on the ERK Western blot has a slight
air bubble just above the ERK band that does not impair quantitation.
www.oncotarget.com
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and demonstrates that TMEM165 induces glycosylation
changes and protein expression changes in breast cancer
that favors EMT. We are the first to report that increased
expression levels of TMEM165 in IDC tumors correlates
with poor prognosis in breast cancer patients. Additionally,

www.oncotarget.com

we have shown that TMEM165 is expressed in DCIS and
increases in early stage IDC making it a potential driver of
tissue invasion. This study is also the first to use CRISPR/
Cas9 gene editing to delete TMEM165 in a human breast
cancer cell line. Our xenograft results confirm that
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Figure 5: TMEM165 expression levels alters N-linked glycosylation. (A) Western blot analysis of NCSTN from MDAMB231

TMEM165KO (clones ACH2 and ACA2) and MDAMB231 Control (clone ACH11) cell lysates before and after PNGaseF treatment.
NCSTN mature, immature, and deglycosylated bands are labeled. The Western blot was imaged on Bio-Rad EZ Imager and has not
been manipulated. Any marks on the blot that are not labeled bands are from forceps handling of the membrane. Right panel shows the
quantification of mature, immature and deglycosylated forms Nicastrin protein levels after normalization with actin (n = 2, **P < 0.01) (B)
Western blot showing different glycoforms of NCSTN in Control and TMEM165KO across different cell lines (MDAMB231, HEK293T
and Hela). NCSTN in Control and TMEM165KO across different cell lines (MDAMB231, HEK293T and Hela). Right panel shows the
quantification of Nicastrin protein levels after normalization with actin (n = 2). (C, D) Western blot showing rescue of NCSTN glycoforms
in TMEM165KO cells after transient transfection with TMEM16WT plasmid and TMEM165CDG mutants (R126H and G304R). Right
panel shows the quantification of Nicastrin protein levels after normalization with actin (n = 2,**P < 0.01). (E) Xenograft paraffin embedded
tissue sections treated with PNGaseF were subjected to Tissue MALDI-FTICR IMS exhibited differential expression of N-glycan structures
among Control and TMEM165KO tumor tissues. Represented glycan structures are in accordance with the guidelines for the Consortium
for Functional Glycomics (CFG): blue square, N-acetylglucosamine (GlcNAc); green circle, mannose (Man); yellow circle, galactose
(Gal); red triangle, fucose (Fuc); purple diamond, N-acetylneuraminic acid (Neu5Ac). (F) Lectin blot analysis of MDAMB231 control and
TMEM165KO cell lysates. (G) Graph representing the relative transcript levels of MGAT5, MGAT4A, MGAT4B, ST6GAL1, FUT8 and
MGAT3 in MDAMB231 control or TMEM165KO cells. Normalized data expressed as fold change are plotted for each gene assayed. Error
bars represent one standard deviation from the mean of triplicate values from n = 3 experiments.

TMEM165 expression promotes the expression of proteins
such as vimentin and suppress E-cadherin expression
promoting the shift to a more mesenchymal phenotype.
These findings place TMEM165 as a regulator for the
epithelial to mesenchymal transition.
In CDG patients, TMEM165 mutations have been
shown to lead to changes in protein splicing that disrupt
the function of TMEM165 leading to glycosylation
changes [12, 31]. In breast cancer, we find that TMEM165
is amplified in expression with no identified mutations. A
previous study observed increased expression of TMEM165
in hepatocellular carcinoma (HCC) and knockdown of
TMEM165 in HCC led to a decrease in invasive disease
[37]. We find that TMEM165 expression increases in IDC
and patients with higher TMEM165 expression levels have
a significant reduction in overall survival. This places
TMEM165 as a potential target for the development of new
therapeutic strategies to improve patient survival.
The functional significance of how TMEM165 alters
N-linked glycosylation is not well understood and the
changes in glycosylation in human patients and zebrafish
models are variable [16, 38, 39]. Possible explanations
include that TMEM165, a Golgi transmembrane protein
and putative ion transporter, is acting as a Mn2+/Ca2+
transporter moving Mn2+ from the Golgi lumen to the
cytosol. Evidence supports a role for TMEM165 in Mn++
transport as the TMEM165 protein is degraded by high
cytosolic Mn2+ concentration [14, 40]. In breast cancer,
calcium ATPases are altered in expression levels and
activity and these findings would further complicate the
control of ion homeostasis [41, 42]. This may account
for our observation that changes in N-linked glycans in
the MDAMB231 breast cancer cells with TMEM165KO
yields a very different migration pattern of the
glycoprotein NCSTN compared with the non-malignant
HEK293T cells and the cervical cancer cell line HeLa. Our
Maldi-FTICR-IMS imaging results indicate an increase in
sialylation and fucosylation on specific N-linked structures
in our xenograft TMEM165KO tissues compared to
control tissues. Our previous glycomic analysis of IDC
www.oncotarget.com

patient tissues revealed an increase in tetra-antennary
fully sialylated structures with polylactosamine in tumor
tissue compared to patient matched normal [43]. In this
study we find that knockout of TMEM165 expression
is changing the expression of key glycosyltransferases
such as Mgat5, Mgat4a, FUT8, and ST6GAL1. Each of
the GT enzymes changing in TMEM165KO tissues has
been linked to promoting cancer invasion in previous
studies [44–48]. However, our xenograft data clearly
indicate that there is a significant reduction in invasion,
vascularization, and growth in TMEM165KO tumors
despite the increase in N-glycan structures thought to
promote invasion. Our current data indicate there may
be more functional significance of the specific N-linked
glycan structures presented at asparagine sites located
on certain glycoproteins that is important for influencing
tumor invasion, as indicated in previous studies examining
changes in glycosylation in clinically advanced breast
cancers [49, 50]. Alternatively, TMEM165 may be leading
to changes in the expression levels of glycoproteins that
function to shift toward a more invasive phenotype and
this global glycoprotein change drives the phenotype
changes. This theory would agree with the fact that
variable changes in N-glycan processing have been
observed in serum proteins from human CDG patients and
these patients all share significant skeletal and cartilage
defects [12, 39, 51]. Future mass-spectrometry studies
identifying the glycoproteins that change expression in
response to TMEM165 expression are needed to better
understand the influence of TMEM165 on cell phenotype.
Our data indicates that both wild-type (WT)
TMEM165 and CDG mutant forms of TMEM165 can
change the glycosylation of NCSTN in MDAMB231
TMEM165KO cells back toward the migration observed
in control cells. We also find that WT and CDG Mutant
forms of TMEM165 can both rescue cell migration in
the TMEM165KO cells (data not shown). These findings
indicate that the mutations in CDG patients associated
with disease defects and changes in glycosylation for these
patients during early development are distinct from the
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regions of the TMEM165 protein controlling migration,
glycosylation changes, and phenotype in breast cancer.
Our analysis of TMEM165 expression levels in
human breast cancer cell lines suggests that there may be
a relationship between ER expression and the control of
TMEM165 expression levels. Human breast cancer cell
lines with ER expression have undetectable levels of
TMEM165 by RT-PCR and Western blot; while cell lines
without ER expression have higher levels of TMEM165.
Our TCGA expression analysis indicates that certain
ER+ breast cancers do express increased TMEM165
(Table 2) although the overall percentages of luminal A
and luminal B cases with TMEM165 expression are lower
than breast cancers that are negative for ER receptor.
We have examined the levels of TMEM165 in ER- and
ER+ metastatic TCGA breast cancer cases and find that
there are significantly higher TMEM165 levels in ERmetastatic cases (p 0.009, Supplementary Figure 2). These
findings support further study as many women with ER +
breast cancers are treated with ER antagonist. It will be
important to determine if the TMEM165 gene is regulated
by the ER receptor and how the levels of TMEM165
change in response to ER receptor antagonist such as
tamoxifen. For example, would ER antagonist treatment
lead to an increase in TMEM165 over time and could this
be linked to recurrence of invasive disease? TMEM165
has recently been linked to milk production during
lactation and these findings would also support potential
hormonal regulation of TMEM165 [19, 20].
In conclusion, we have expanded on our initial
2012 glycoproteomic study that was the first to
identify TMEM165 protein as a potential biomarker
for breast carcinoma. In this study we have provided
initial mechanistic studies that indicate that TMEM165
expression drives the growth and invasion of breast
cancer. TMEM165 expression levels could be a potential
prognostic marker for predicting DCIS cases that may
progress to invasive disease. Larger prospective cohorts
will need to be analyzed to determine the link between
TMEM165 levels and the progression to IDC. We find
that IDC patients with higher TMEM165 expression levels
have reduced overall survival making this protein a target
for the development of new therapeutic strategies to limit
the progression of breast cancer.

between the higher and lower expression groups. Log rank
p values and hazard ratios with 95% confidence intervals
were then calculated.

Gene expression analysis via UALCAN
UALCAN (http://ualcan.path.uab.edu/) is an online,
open-access platform for visualization of gene expression
alterations occurring between cancerous and paired
normal tissues relative to clinical pathological features,
which are sourced from the TCGA database [18]. In
the current study, UALCAN was applied to analyze the
transcriptional levels of TMEM165 in primary breast
cancer tissues and its association with molecular subtypes.
All the breast cases available on UALCAN were included
in our research.

Scratch wound assay
MDAMB231 cells were seeded into a 6-well plate
at high density in DMEM (Invitrogen) with 10% FBS
(Gemini Bioproducts, West Sacramento, CA) and 100 mg/
mL streptomycin (Invitrogen). A clear area was scraped
into the cell monolayer using a pipet tip. Cells were
washed gently with PBS to remove the detached cells,
placed in complete growth media for 2 days. Migration of
cells into the wounded area was monitored by microscopy
using a Cytation 3 (BioTek) and images were captured at
different time points after the scratch (0 hr, 24 hr and 48
hr). Wound closure was quantified using ImageJ software
(http://imagej.nih.gov/ij/docs/index.html).

Boyden chamber assay
Boyden chamber assay was preformed using Cell
culture inserts Transparent PET membrane (Corning, Life
sciences, USA) with 8 µm pore size in 24-well dishes.
Approximately 4 × 105 cells in 200 µl of complete
medium were seeded into the upper chamber and 500 µl
of complete medium placed in the lower chamber. The
next day, the cells in the upper chamber were replenished
with serum-free medium. The lower chamber was replaced
with complete medium to allow migration of cells for 48
hrs. Cells on the inside of the filters were removed and
cells that had migrated to the underside of the filters were
stained with crystal violet. Five random fields from n = 3
experiments were counted.

MATERIALS AND METHODS
Kaplan–Meier plot analysis

Invasion assay

The prognostic value of the TMEM165 gene in
breast cancer was analyzed using the online Kaplan–Meier
plotter (http://kmplot.com/analysis/) [52–54]. For analysis,
patients with breast cancer were divided into two groups
according to higher and lower TMEM165 expression levels
(specifications regarding cutoffs are included in the figure
legend). The overall survival (OS) was then compared
www.oncotarget.com

Chemicon invasion assays (ECM554, Millipore,
Billerica, MA) were used to test invasiveness. Briefly,
cells were washed in serum-free medium, a cell suspension
made at 0.5 × 106 cells/ml. 250 µL cell suspension was
then added to rehydrated invasion membranes. Serum
(10%) in serum-free medium was added to the lower
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chamber as chemoattractant and the plates incubated for 24
hrs at 37°C before detection, according to manufacturer’s
instructions using a fluorescent plate reader.

program accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International
(AAALAC) and has an assurance on file with the Office of
Laboratory Animal Welfare (OLAW). Six-week-old female
immunodeficient mice were obtained by Jackson Labs NSG,
NOD scid/6 weeks old. Two million cells, MDAMB231
Control or TMEM165KO, were injected subcutaneously
into the right or left flank (respectively) of n = 10 mice.
Mice were monitored daily for 6 weeks prior to necropsy
and tumor extraction. Tumor volume in mg is calculated
using the following formula: volume _ (length × width2/2).
Procedures were performed at The University of
Oklahoma Health Sciences Center under an approved
animal use protocol. All methods were performed in
accordance with guidelines and regulations at OUHSC.
Mouse mammary gland with human DCIS xenograft tissue
sections were obtained from Dr. Bethany Hannafon. NOD
scid gamma mice were injected with 10,000 MCF10DCIS.
com cells per gland (Left and Right) and allowed to
develop into DCIS and IBC. The mice were sacrificed
after 40 days and tumor sections were collected.

Cell staining
MDAMB231
control
and
MDAMB231
TMEM165KO cells were plated on coverslips that were
pre-coated with 10 µg/mL Fibronectin. Cells were allowed
to adhere overnight in 37°C CO2 incubator. Attached
cells were washed twice with PBS then fixed with 4%
Paraformaldehyde for 20 minutes and washed twice with
PBS. Cells were permeabilized with 0.1% Triton X-100 in
PBS for 15 min, washed with PBS, then stained with Alexa
Fluor 568-conjugated phalloidin 1:40 dilution (Invitrogen,
Molecular Probes). Cells for staining with vimentin and
E-cadherin were fixed in cold methanol for 5 minutes prior
to blocking and addition of primary antibodies against
Vimentin and E-Cadherin (1:200 dilution) (Cell Signaling)
in PBS-T/1% BSA overnight at 4°C. The next day after
washing the cells were incubated with Alexa Fluor 488
conjugated goat anti-rabbit for 1 hr at room temperature.
Nuclei were counterstained with a 1:10,000 solution of
DAPI for 10 seconds before mounting in Prolong Gold
Antifade (ThermoFisher). Stained cells were imaged using
EVOS M7000 microscope.

Immunohistochemistry staining
Paraffin-embedded tissue sections from control and
TMEM165KO tumors were de-waxed and re-hydrated.
Tissues were blocked with 0.5% hydrogen peroxide for
30 minutes. Tissues were rinsed in PBS with 0.2% tween
20 prior to blocking in 2.5% blocking serum (Vector
Labs) for 20 minutes. The antibodies Ki67 (Santa Cruz
Biotechnology) (1:100), E-cadherin (Cell Signaling)
(1:200), vimentin (Cell Signaling) (1:200), or CD31
(Abcam) (1:50) were diluted in PBS/0.2% tween 20 and
added for 1 hr at room temperature. Following washes
in PBS/0.2% tween 20 the tissues were incubated with
the ABC reagent (Vector Labs) for 30 minutes. Positive
staining was detected using DAB substrate followed by
hematoxylin counterstain and mounted. Images were
captured with an Aperio Scanscope (Leica Biosystems).

Western blot
Cells were harvested in RIPA buffer (1× PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS.
BT549 and HS57T cell lysate were purchased from
Origene. 20 µg total lysate protein was heated to 60°C
for 5 mins in SDS sample buffer and separated on 4–12%
Bis Tris polyacrylamide gels (Invitrogen) before transfer
to PVDF membrane. Membranes were blocked overnight
at 4°C in 5% nonfat milk/1XTBS/.05% tween-20 (TBST
Blotto). After blocking the membranes were incubated
in primary antibodies anti-TMEM165 (1:1000) and
anti-β Actin (1:500) antibodies (Sigma–Aldrich), anti-Ecaderin (1:500) (Cell Signaling), anti-vimentin 1:1,000
(Cell Signaling) anti –Nicastrin (1:500) (R&D Systems)
diluted with 1× TBST Blotto for 1 hr at room temperature.
After washing, the membranes were incubated with goat
anti-rabbit or goat anti-mouse immunoglobulins HRP
conjugated were purchased from Santa Cruz diluted (1:
10,000) in TBST at room temperature for 30 min. Washed
blots were developed in ECL substrate (Thermo Scientific).

CRISPR-Cas9 gene editing
MDAMB231 cells were maintained in DMEM
media supplemented with 10% FBS without antibiotics.
For creation of the CRISPR KO cells, media was
changed to 2 mL OPTI-MEM without FBS/antibiotics
and transfected using Life Technologies recommended
protocol for MDA-MB-231 cells (Lipofectamine 3000
with Plus reagent). Transfections were carried out in a
6-well plate using an equal amount of Cas9 DNA plus
TMEM165 CRISPR “A” guide RNA target sequence
(GeneCopoeia) totaling 2.5 ug of DNA per well.
Transfection was allowed to be carried out for 5 hrs at
which time the transfected cells were supplemented with
an equal volume of standard media. Twenty four hrs
after transfection the media was completely changed to

Mouse xenograft model
All procedures were performed at The University
of Arkansas for Medical Sciences (UAMS) under an
approved animal use protocol. All methods were performed
in accordance with guidelines and regulations at UAMS.
UAMS maintains a centralized animal care and use
www.oncotarget.com
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standard media. Two weeks after transfection, live cells
were single cell sorted into 3 × 96 well plates. Single cell
colonies were grown to at least 50% confluence and split
into 24-well plates to be tested by immunofluorescence for
staining with TMEM165 antibodies. Colonies that did not
stain with TMEM165 antibodies were validated as KOs by
Western blot and DNA analysis.

instrument using RT SYBR Green/Fluorescein qPCR
Master Mix (Bio-Rad). Relative expression of target genes
was calculated using the comparative cycle threshold
method with genes normalized to RPL4. Triplicate Ct
values for each gene were averaged and the SD from the
mean was calculated.

Tissue MALDI imaging

Glycosidase digestion

Tissue MALDI imaging was performed as
described previously using a standardized protocol [33,
50, 56]. Briefly, formalin-fixed paraffin embedded tumor
tissues were antigen retrieved followed by spraying of
a molecular coating of PNGaseF using a TMSprayer
(HTX Technologies LLC., Chapel Hill, NC). After a 2 hr
incubation, slides were dessicated and 7 mg/ml CHCA
matrix was applied using the TMSprayer. Slides were
stored in a desiccator until MALDI-FTICR MS analysis.
Spectra were acquired across the entire tissue section on a
Solarix dual source 7T FTICR mass spectrometer (Bruker
Daltonics) to detect the N-glycans with a SmartBeam II
laser operating at 2000 Hz, a laser spot size of 25 µm and a
raster width of 125 µm unless otherwise indicated. Images
of differentially expressed glycans were generated to view
the expression pattern of each analyte of interest using
FlexImaging 4.0 software (Bruker Daltonics) and structural
representations of these m/z values were generated using
GlycoWorkbench based on previous studies [57].

To remove N-glycans, protein extracts were
digested with PNGaseF using the protocol as described
by the vendor New England Biolabs. Briefly, 20 µg of
glycoprotein were combined with 1 µl of Glycoprotein
Denaturing Buffer (10×) and H2O to make a 10 µl
total reaction volume. To denature glycoproteins, the
reaction was subjected to heat at 100°C for 10 minutes.
The denatured glycoproteins were chilled on ice and
centrifuged 10 seconds. To make a total reaction volume
of 20 µl, 2 µl GlycoBuffer 2 (10×), 2 µl 10% NP-40 and 6
µl H2O was added. 1 µl PNGase F was added and gently
mixed. The reaction was incubated at 37°C for 1 hr. Then
the samples were run on SDS- polyacrylamide gel to
analyze the extent of de-glycosylation.

Lectin blot analysis
The cells were lysed in RIPA buffer (1× PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS)
containing protease inhibitor. The lysate was cleared
by centrifugation at 10 000× g for 10 min. Protein
concentrations were determined by BCA assay (Pierce,
Rockford, IL). Twenty µg of proteins were separated on
4–12% NuPage Bis Tris gels and transferred to PVDF
membrane at 25 V for 1.5 h. Membranes were blocked
overnight in 3% BSA/TBST buffer before lectin blot
detection using a 1:5000 dilution of the following
biotinylated lectins: (Sambucus nigra (SNL), (SNL),
Aleuria aurantia (AAL), and Datura stramonium (DSL),
Concanavalin A (ConA) (Vector Labs). Bound lectin was
detected using a 1:10,000 dilution of streptavidin–HRP
(Vector Labs) before washing and detection using Western
Lightening Plus (Perkin Elmer).

Transfection
MDAMB231 Control and TMEM165KO cells
were transfected with TMEM165/GFP WT, TMEM165/
GFP R126H, TMEM165/GFP G304R or vector plasmid.
Transfections were performed using lipofectamine
2000 (Invitrogen) following the instructions of the
manufacturer. After 24 hrs of transfection, scratch wound
assay was performed as described above and cells were
scraped for western blot analysis.

Abbreviations
CRISPR: clustered regularly interspaced short
palindromic repeats; Cas9: CRISPR associated protein
9; TMEM165: transmembrane protein 165; EMT:
epithelial-to-mesenchymal transition; IDC: invasive ductal
carcinoma; DCIS: ductal carcinoma in situ; NCSTN:
nicastrin; CDG: congenital diseases of glycosylation;
FTICR: Fourier-transform ion cyclotron resonance; AAL:
Aleuria Aurantia Lectin; DSL: Datura Stramonium Lectin;
SNA: Sambucus Nigra Lectin.

Real time PCR
qRT-PCR was performed as described previously
[55]. Briefly, Samples (50 µl of packed cells) were
extracted using TRIzol (Invitrogen) according to the
manufacturer’s instructions. After DNase treatment,
RNA (2 µg) was reverse-transcribed using Superscript
III (Invitrogen) with random hexamers and oligo (dT).
Primers were validated with respect to primer efficiency
and single product detection. The primer sequences are
shown in Supplementary Table 1. Quantitative realtime PCR was performed in a Bio-Rad CFX96 C1000
www.oncotarget.com
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